Cyclerion Therapeutics In... (CYCN)
Cyclerion Therapeutics Statistics
Share Statistics
Cyclerion Therapeutics has 2.71M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 2.71M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0.02% |
| Shares Floating | 1.64M |
| Failed to Deliver (FTD) Shares | 3.08K |
| FTD / Avg. Volume | 0.16% |
Short Selling Information
The latest short interest is 41.89K, so 1.65% of the outstanding shares have been sold short.
| Short Interest | 41.89K |
| Short % of Shares Out | 1.65% |
| Short % of Float | 2.48% |
| Short Ratio (days to cover) | 2.45 |
Valuation Ratios
The PE ratio is -2.65 and the forward PE ratio is -0.14. Cyclerion Therapeutics's PEG ratio is 0.03.
| PE Ratio | -2.65 |
| Forward PE | -0.14 |
| PS Ratio | 4.05 |
| Forward PS | 0.1 |
| PB Ratio | 0.92 |
| P/FCF Ratio | -1.87 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Cyclerion Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.83, with a Debt / Equity ratio of 0.
| Current Ratio | 5.83 |
| Quick Ratio | 5.83 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $2M |
| Profits Per Employee | $-3.06M |
| Employee Count | 1 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -14.6% in the last 52 weeks. The beta is 1.96, so Cyclerion Therapeutics's price volatility has been higher than the market average.
| Beta | 1.96 |
| 52-Week Price Change | -14.6% |
| 50-Day Moving Average | 2.77 |
| 200-Day Moving Average | 2.88 |
| Relative Strength Index (RSI) | 54.07 |
| Average Volume (20 Days) | 1.93M |
Income Statement
In the last 12 months, Cyclerion Therapeutics had revenue of 2M and earned -3.06M in profits. Earnings per share was -1.21.
| Revenue | 2M |
| Gross Profit | 2M |
| Operating Income | -3.63M |
| Net Income | -3.06M |
| EBITDA | -3.63M |
| EBIT | -3.63M |
| Earnings Per Share (EPS) | -1.21 |
Balance Sheet
The company has 3.23M in cash and 0 in debt, giving a net cash position of 3.23M.
| Cash & Cash Equivalents | 3.23M |
| Total Debt | 0 |
| Net Cash | 3.23M |
| Retained Earnings | -267.49M |
| Total Assets | 9.57M |
| Working Capital | 3.5M |
Cash Flow
In the last 12 months, operating cash flow was -4.33M and capital expenditures 0, giving a free cash flow of -4.33M.
| Operating Cash Flow | -4.33M |
| Capital Expenditures | 0 |
| Free Cash Flow | -4.33M |
| FCF Per Share | -1.72 |
Margins
Gross margin is 100%, with operating and profit margins of -181.4% and -152.85%.
| Gross Margin | 100% |
| Operating Margin | -181.4% |
| Pretax Margin | -152.85% |
| Profit Margin | -152.85% |
| EBITDA Margin | -181.4% |
| EBIT Margin | -181.4% |
| FCF Margin | -216.65% |
Dividends & Yields
CYCN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for CYCN.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on May 16, 2023. It was a backward split with a ratio of 1:20.
| Last Split Date | May 16, 2023 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -33.31 |
| Piotroski F-Score | 3 |